Delcath Systems's top three insider shareholders as of September 09, 2026 are Advisors, Inc. Rosalind (Director, 3.41Mn shares), Steven A J Salamon (Director, 3.41Mn shares), Advisors, Inc. Rosalind (Director, 3.41Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Advisors, Inc. Rosalind | Director | 0 | 6,636,251 | 6,636,251 | 33.6% | 09 May, 2025 |
| 2 | Steven A J Salamon | Director | 455,315 | 6,146,054 | 6,601,369 | 33.5% | 09 May, 2025 |
| 3 | Gil Aharon | Director | 0 | 6,094,739 | 6,094,739 | 30.9% | 09 May, 2025 |
| 4 | Vojo Vukovic | Chief Medical Officer | 168,882 | 0 | 168,882 | 0.9% | 13 Jun, 2025 |
| 5 | Sandra Pennell | Chief Financial Officer | 77,018 | 0 | 77,018 | 0.4% | 06 Mar, 2026 |
| 6 | David L. Hoffman | Gen'L Counsel, Cco Secy | 74,330 | 0 | 74,330 | 0.4% | 19 Mar, 2024 |
| 7 | John Purpura | Chief Operating Officer | 41,526 | 0 | 41,526 | 0.2% | 17 Oct, 2023 |
| 8 | Kevin Muir | Gm Interventional Oncology | 18,582 | 0 | 18,582 | 0.1% | 19 Mar, 2024 |
| 9 | John Richard Sylvester | Director | 14,936 | 0 | 14,936 | 0.1% | 25 Nov, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 13 May, 2026 | Bridget A Martell | Director | Acquired A | 22,500 | $0.00 | $0 | 22,500 | Direct |
| 13 May, 2026 | John Richard Sylvester | Director | Acquired A | 22,500 | $0.00 | $0 | 22,500 | Direct |
| 13 May, 2026 | Gil Aharon | Director | Acquired A | 22,500 | $0.00 | $0 | 22,500 | Direct |
| 13 May, 2026 | Elizabeth Czerepak | Director | Acquired A | 22,500 | $0.00 | $0 | 22,500 | Direct |
| 13 May, 2026 | Steven A J Salamon | Director | Acquired A | 22,500 | $0.00 | $0 | 22,500 | Direct |
| 06 Mar, 2026 | Sandra Pennell | Chief Financial Officer | Acquired P | 5,533 | $9.04 | $50.02K | 77,018 | Direct |
| 06 Mar, 2026 | Sandra Pennell | Chief Financial Officer | Acquired P | 5,533 | $9.04 | $50.02K | 77,018 | Direct |
| 06 Mar, 2026 | Sandra Pennell | Chief Financial Officer | Acquired P | 5,533 | $9.04 | $50.02K | 77,018 | Direct |
| 06 Mar, 2026 | Sandra Pennell | Chief Financial Officer | Acquired P | 5,533 | $9.04 | $50.02K | 77,018 | Direct |
| 02 Mar, 2026 | Gerard J Michel | Chief Executive Officer | Acquired P | 11,200 | $8.96 | $100.31K | 342,034 | Direct |
| 17 Feb, 2026 | Kevin Muir | Gm Interventional Oncology | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |
| 17 Feb, 2026 | Vojo Vukovic | Chief Medical Officer | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |
| 17 Feb, 2026 | Sandra Pennell | Chief Financial Officer | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |
| 17 Feb, 2026 | David L. Hoffman | Gen'L Counsel, Cco Secy | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |
| 17 Feb, 2026 | David L. Hoffman | Gen'L Counsel, Cco Secy | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |
| 17 Feb, 2026 | Martha S. Rook | Chief Operating Officer | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |
| 17 Feb, 2026 | Martha S. Rook | Chief Operating Officer | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |
| 17 Feb, 2026 | Kevin Muir | Gm Interventional Oncology | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |
| 17 Feb, 2026 | David L. Hoffman | Gen'L Counsel, Cco Secy | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |
| 17 Feb, 2026 | Vojo Vukovic | Chief Medical Officer | Acquired A | 56,500 | $0.00 | $0 | 56,500 | Direct |